Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COHERUS BIOSCIENCES, INC.

(CHRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Advancing This Afternoon But Biotech Struggle

08/19/2021 | 01:53pm EDT


ę MT Newswires 2021
All news about COHERUS BIOSCIENCES, INC.
10/13COHERUS BIOSCIENCES : Mourns the Passing of Board Member Alan C. Mendelson - Form 8-K
PU
10/13COHERUS BIOSCIENCES, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
10/11COHERUS BIOSCIENCES : Mourns the Passing of Board Member Alan C. Mendelson
GL
10/11Coherus Biosciences, Inc. Announces Demise of Alan C. Mendelson, Director
CI
10/05COHERUS BIOSCIENCES' : Udenyca On-Body Injector Trial Meets Endpoints
MT
10/05COHERUS BIOSCIENCES : Announces Positive Results of UDENYCA« On-Body Injector Clinical Tri..
AQ
10/05Coherus BioSciences, Inc. Announces Positive Results of UDENYCA« On-Body Injector Clini..
CI
10/04COHERUS BIOSCIENCES : Positive Results of Clinical Trial Comparing Coherus' Ranibizumab Bi..
AQ
10/04Coherus Biosciences, Inc. Announces Positive Results of Clinical Trial Comparing Coheru..
CI
10/01COHERUS BIOSCIENCES : FDA Accepts Coherus Application to Market Biosimilar Version of Luce..
MT
More news
Analyst Recommendations on COHERUS BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 354 M - -
Net income 2021 -174 M - -
Net cash 2021 31,4 M - -
P/E ratio 2021 -5,97x
Yield 2021 -
Capitalization 1 300 M 1 300 M -
EV / Sales 2021 3,58x
EV / Sales 2022 3,48x
Nbr of Employees 311
Free-Float 88,5%
Chart COHERUS BIOSCIENCES, INC.
Duration : Period :
Coherus BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COHERUS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 17,00 $
Average target price 26,29 $
Spread / Average Target 54,6%
EPS Revisions
Managers and Directors
Denny M. Lanfear Chairman, President & Chief Executive Officer
McDavid Stilwell Chief Financial Officer
Barbara K. Finck Chief Medical Officer
Vladimir Vexler Chief Scientific Officer
Vincent R. Anicetti Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
COHERUS BIOSCIENCES, INC.-2.19%1 300
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156